Genevra Galura1, Sana J Said1, Pooja A Shah1, Alexandria M Hissong1, Nikunj K Chokshi2, Karen R Fauman3, Rebecca Rose4, Deborah S Bondi1. 1. Department of Pharmacy (GG, SJS, PAS, AMH, DSB), University of Chicago Medicine, Chicago, IL. 2. Section of Pediatric Surgery (NKC), Department of Surgery, University of Chicago, Chicago, IL. 3. Section of Pediatric Critical Care (KRF), Department of Pediatrics, University of Chicago, Chicago, IL. 4. Department of Cardiac Surgery (RR), University of Chicago Medicine, Chicago, IL.
Abstract
OBJECTIVE: To evaluate an institutional practice change from an extracorporeal life support (ECLS) anticoagulation monitoring strategy of activated clotting time (ACT) alone to a multimodal strategy including ACT, activated partial thrombin time, heparin anti-factor-Xa, and thromboelastography. METHODS: This was a retrospective review of patients younger than 18 years on ECLS and heparin between January 2014 and June 2020 at a single institution. RESULTS: Twenty-seven patients used an ACT-directed strategy and 25 used a multimodal strategy. The ACT-directed group was on ECLS for a shorter median duration than the multimodal group (136 versus 164 hours; p = 0.046). There was a non-significant increase in major hemorrhage (85.1% versus 60%; p = 0.061) and a significantly higher incidence of central nervous system (CNS) hemorrhage in the ACT-directed group (29.6% versus 0%; p = 0.004). Rates of thrombosis were similar, with a median of 3 circuit changes per group (p = 0.921). The ACT-directed group had larger median heparin doses (55 versus 34 units/kg/hr; p < 0.001), required more dose adjustments per day (3.8 versus 1.7; p < 0.001), and had higher rates of heparin doses >50 units/kg/hr (62.9% versus 16%; p = 0.001). More anticoagulation parameters were supratherapeutic (p = 0.015) and fewer were therapeutic (p < 0.001) in the ACT-directed group. CONCLUSIONS: Patients with a multimodal strategy for monitoring anticoagulation during ECLS had lower rates of CNS hemorrhage and decreased need for large heparin doses of >50 units/kg/hr without an increase in clotting complications, compared with ACT-directed anticoagulation. Multimodal anticoagulation monitoring appears superior to ACT-only strategies and may reduce heparin exposure and risk of hemorrhagic complications for pediatric patients on ECLS. Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: membership@pediatricpharmacy.org 2022.
OBJECTIVE: To evaluate an institutional practice change from an extracorporeal life support (ECLS) anticoagulation monitoring strategy of activated clotting time (ACT) alone to a multimodal strategy including ACT, activated partial thrombin time, heparin anti-factor-Xa, and thromboelastography. METHODS: This was a retrospective review of patients younger than 18 years on ECLS and heparin between January 2014 and June 2020 at a single institution. RESULTS: Twenty-seven patients used an ACT-directed strategy and 25 used a multimodal strategy. The ACT-directed group was on ECLS for a shorter median duration than the multimodal group (136 versus 164 hours; p = 0.046). There was a non-significant increase in major hemorrhage (85.1% versus 60%; p = 0.061) and a significantly higher incidence of central nervous system (CNS) hemorrhage in the ACT-directed group (29.6% versus 0%; p = 0.004). Rates of thrombosis were similar, with a median of 3 circuit changes per group (p = 0.921). The ACT-directed group had larger median heparin doses (55 versus 34 units/kg/hr; p < 0.001), required more dose adjustments per day (3.8 versus 1.7; p < 0.001), and had higher rates of heparin doses >50 units/kg/hr (62.9% versus 16%; p = 0.001). More anticoagulation parameters were supratherapeutic (p = 0.015) and fewer were therapeutic (p < 0.001) in the ACT-directed group. CONCLUSIONS: Patients with a multimodal strategy for monitoring anticoagulation during ECLS had lower rates of CNS hemorrhage and decreased need for large heparin doses of >50 units/kg/hr without an increase in clotting complications, compared with ACT-directed anticoagulation. Multimodal anticoagulation monitoring appears superior to ACT-only strategies and may reduce heparin exposure and risk of hemorrhagic complications for pediatric patients on ECLS. Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: membership@pediatricpharmacy.org 2022.
Authors: Anna Liveris; Ricardo A Bello; Patricia Friedmann; Melissa A Duffy; Deepa Manwani; James S Killinger; Daniel Rodriquez; Samuel Weinstein Journal: Pediatr Crit Care Med Date: 2014-02 Impact factor: 3.624
Authors: Craig A Nankervis; Thomas J Preston; Kevin C Dysart; Whitney D Wilkinson; Louis G Chicoine; Stephen E Welty; Leif D Nelin Journal: ASAIO J Date: 2007 Jan-Feb Impact factor: 2.872
Authors: Christopher W Baird; David Zurakowski; Barbara Robinson; Sanjiv Gandhi; Leighann Burdis-Koch; Joseph Tamblyn; Ricardo Munoz; Karol Fortich; Frank A Pigula Journal: Ann Thorac Surg Date: 2007-03 Impact factor: 4.330
Authors: Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: Michael S Northrop; Robert F Sidonio; Sharon E Phillips; Andrew H Smith; Hardison C Daphne; John B Pietsch; Brian C Bridges Journal: Pediatr Crit Care Med Date: 2015-01 Impact factor: 3.624
Authors: Jane S Yu; Ryan P Barbaro; Donald A Granoski; Mary E Bauman; M Patricia Massicotte; Laurance L Lequier; Gail M Annich; Lindsay M Ryerson Journal: Pediatr Crit Care Med Date: 2017-11 Impact factor: 3.624
Authors: Timothy M Maul; Erin L Wolff; Bradley A Kuch; Adam Rosendorff; Victor O Morell; Peter D Wearden Journal: Pediatr Crit Care Med Date: 2012-11 Impact factor: 3.624